Adverse Drug Reaction News Bulletins
ADR News Bulletin 2023 May (Volume 25 Number 1)
Audiences
Healthcare professional
Industry member
Product type
Therapeutic Products
16 May 2023
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Bulletin Highlights:
Analysis of adverse event reports with COVID-19 therapeutics for the treatment or prophylaxis of COVID-19
Analysis of adverse event reports for health products for year 2022
Analysis of COVID-19 vaccine adverse event reports for year 2022
High-dose vitamin B6 and risk of peripheral neuropathy
Navigation made easy – explore HSA’s website for adverse event reporting and safety information related to health products
Click on the link below to download the issue in pdf:
ADR_News_May2023_Vol25_No [PDF, 2520 KB]
New drugs approved in 2022:
Healthcare professionals are encouraged to report all serious and non-serious
suspected adverse drug reactions (ADRs) with the use of new drugs. Your active
participation in the ADR monitoring programme will provide valuable support to
the post-marketing surveillance on drug safety.
Click on the link below to download the issue in pdf: